EGF and cancer: Treatment with AZA1 at 2, 5 and 10 μM significantly reduced the relative expression ratio of F- to G-actin in all three cell lines after 24 h compared to EGF-stimulated cancer cells (p<0.01; Figure 4C) and control cells (p<0.05; Figure 4C).